Catalent in deal to buy gene therapy contract manufacturer Paragon for $1.2B
The deal follows by weeks Thermo Fisher's acquisition, for $1.7 billion, of gene therapy contract manufacturing organization Brammer Bio.
The deal follows by weeks Thermo Fisher's acquisition, for $1.7 billion, of gene therapy contract manufacturing organization Brammer Bio.
Brammer specializes in contract services for viral vector-based gene therapies. Panelists at a conference last week stressed the importance of manufacturing for gene therapy investors.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
With the $1.7 billion acquisition of CRO and manufacturing company Lake Region Medical, Texas-based CRO Greatbatch has become one of the largest medtech-focused CROs in the world.
Paragon Bioservices – a contract research and manufacturing organization, has closed a $13 million round of Series A financing. The Baltimore company’s focused on biologicsĀ and vaccine work. The financing was led by NewSpring Capital and Camden Partners. Paragon CEO Marco Chacon described the fundraise as indicative of “an inflection point for the company,” now that […]